Drug Combination on Exercise Performance at High Altitude
Phase 2
Completed
- Conditions
- Acute Mountain Sickness
- Interventions
- Drug: placebo
- Registration Number
- NCT01902758
- Lead Sponsor
- University of Montana
- Brief Summary
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 28
Inclusion Criteria
- healthy males
Exclusion Criteria
- VO2max below 45ml/kg/min
- currently taking any medication
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ambrisentan and theophylline ambrisentan and theophylline ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days placebo placebo matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
- Primary Outcome Measures
Name Time Method Time (Minutes) to Complete 2 Miles on a Treadmill after arriving at high altitude (within 1 hour)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Montana Center for Work Physiology and Exercise Metabolism
🇺🇸Missoula, Montana, United States